20 May 2023
BerGenBio ASA – Updated key information relating to the preferential rights issue
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 25 April 2023 with key information relating to the preferential rights issue in the Company.
Date on which the terms and conditions of the preferential rights issue were announced: 25 April 2023 and 20 May 2023
Last day including right: 22 May 2023
Ex-date: 23 May 2023
Record Date: 24 May 2023
Date of approval: 22 May 2023
Maximum number of new shares: 2,500,000,000
Subscription price: NOK 0.10
Ratio preferential rights: Each existing shareholder as of 22 May 2023 (and being registered as such in Euronext Securities Oslo, the Norwegian Central Securities Depository, (the VPS) as at the expiry of 24 May 2023 (the record date)) will be granted 28.197440 subscription rights for each share registered as held by the shareholder. The number of subscription rights granted to each existing shareholder will be rounded down to the nearest whole subscription right.
Subscription ratio: 1:1 (number of new shares per subscription right)
Managers: Arctic Securities AS and Carnegie AS
Will the rights be listed: Yes (ticker code “BGBIT”)
ISIN for the preferential rights: ISIN NO 0012921180
Other information: The subscribers in the Rights Issue will without cost be allocated one warrant (Nw. “frittstående tegningsrett”) issued by the Company for every two new shares allocated to, and paid by, them in the Rights Issue. The number of warrants to be issued will be minimum 843,750,000 and maximum 1,250,000,000. Each warrant will give the holder a right to subscribe for one new share in the Company at a subscription price equal to the volume-weighted average price (VWAP) of the Company’s shares on the Oslo Stock Exchange on the three last trading days prior to the first date on which the holder can exercise the warrant in each exercise period (as described below) less 30%, but in any event not exceeding the subscription price in the Rights Issue plus 30% (i.e. NOK 0.13. The warrants may be exercised during two exercise periods: (i) within the first 14 days after the Company’s announcement of its Q3 2023 quarterly financial report and (ii) from 1 April 2024 to 14 April 2024.
The preferential rights issue is subject to approval by the annual general meeting of the Company, which will be held on 22 May 2023.
This information is published in accordance with the requirements of the Continuing Obligations.
For further information, please contact:
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Graham Morrell
graham.morrell@bergenbio.com
For information about the Rights Issue please contact the Managers:
Arctic Securities AS, tel.: + 47 21 01 30 40
Carnegie AS, tel.: +47 22 00 93 40
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
